Literature DB >> 21472849

Methodological comparison of two anti-ZAP-70 antibodies.

Heba A Degheidy1, David J Venzon, Mohammed Z H Farooqui, Fatima Abbasi, Diane C Arthur, Wyndham H Wilson, Adrian Wiestner, M A Stetler-Stevenson, Gerald E Marti.   

Abstract

BACKGROUND: ZAP-70 expression is a stage independent prognostic marker in CLL. However, interlaboratory variation is large, and there is neither a consensus nor a regulatory approved methodology.
METHODS: Two anti-ZAP70 clones (1E7.2 and SBZAP) were compared in 45 untreated CLL patients. Nine different methods for ZAP-70 expression analysis were evaluated: M1, isotype control to determine negative; M2, internal residual T-cell to determine positive; M3, normal donor (ND) T-cell to determine positive; M4, internal T-cell/clone ratio; M5, ND residual T-cell/clone ratio; M6, clone/normal remaining B-cell ratio; M7, clone/ND B- cell ratio; M8, CLL-Z score; M9, modified CLL-Z score. A scoring system was designed integrating both 1E7.2 and SBZAP clones to assign ZAP-70 expression.
RESULTS: The correlation coefficients for the four selected highest statistically significant methods were as follows (M1 = 0.71, M3 = 0.72, M7 = 0.67, and M9 = 0.64). These four methods were used to generate a combined score. The two reagents showed agreement using the designed scoring system for 37/45 samples (82%), and 8/45 (18%) showed equivocal result with one of the two clones. Seven of the eight equivocal samples were resolved using the scoring system.
CONCLUSIONS: Four of the nine methods of analysis were compared for each reagent. The use of two independent ZAP-70 reagents increases analytical certitude and the scoring method aids in the resolution of equivocal results. The combined use of two reagents, four methods of analysis, and a scoring method allowed for assignment of ZAP-70 expression in 44/45 samples (98%) tested and improved performance of this important prognostic assay. Published 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21472849      PMCID: PMC3461319          DOI: 10.1002/cyto.b.20591

Source DB:  PubMed          Journal:  Cytometry B Clin Cytom        ISSN: 1552-4949            Impact factor:   3.058


  20 in total

1.  Clinical staging of chronic lymphocytic leukemia.

Authors:  K R Rai; A Sawitsky; E P Cronkite; A D Chanana; R N Levy; B S Pasternack
Journal:  Blood       Date:  1975-08       Impact factor: 22.113

2.  ZAP-70 expression and prognosis in chronic lymphocytic leukaemia.

Authors:  Jenny A Orchard; Rachel E Ibbotson; Zadie Davis; Adrian Wiestner; Andreas Rosenwald; Peter W Thomas; Terry J Hamblin; Louis M Staudt; David G Oscier
Journal:  Lancet       Date:  2004-01-10       Impact factor: 79.321

3.  ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.

Authors:  Laura Z Rassenti; Lang Huynh; Tracy L Toy; Liguang Chen; Michael J Keating; John G Gribben; Donna S Neuberg; Ian W Flinn; Kanti R Rai; John C Byrd; Neil E Kay; Andrew Greaves; Arthur Weiss; Thomas J Kipps
Journal:  N Engl J Med       Date:  2004-08-26       Impact factor: 91.245

Review 4.  B-cell chronic lymphocytic leukemia: a bird of a different feather.

Authors:  F Caligaris-Cappio; T J Hamblin
Journal:  J Clin Oncol       Date:  1999-01       Impact factor: 44.544

Review 5.  Diagnostic criteria for monoclonal B-cell lymphocytosis.

Authors:  Gerald E Marti; Andy C Rawstron; Paolo Ghia; Peter Hillmen; Richard S Houlston; Neil Kay; Thérèse A Schleinitz; Neil Caporaso
Journal:  Br J Haematol       Date:  2005-08       Impact factor: 6.998

6.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.

Authors:  R N Damle; T Wasil; F Fais; F Ghiotto; A Valetto; S L Allen; A Buchbinder; D Budman; K Dittmar; J Kolitz; S M Lichtman; P Schulman; V P Vinciguerra; K R Rai; M Ferrarini; N Chiorazzi
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

7.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

Authors:  T J Hamblin; Z Davis; A Gardiner; D G Oscier; F K Stevenson
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

8.  ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.

Authors:  Adrian Wiestner; Andreas Rosenwald; Todd S Barry; George Wright; R Eric Davis; Sarah E Henrickson; Hong Zhao; Rachel E Ibbotson; Jenny A Orchard; Zadie Davis; Maryalice Stetler-Stevenson; Mark Raffeld; Diane C Arthur; Gerald E Marti; Wyndham H Wilson; Terry J Hamblin; David G Oscier; Louis M Staudt
Journal:  Blood       Date:  2003-02-20       Impact factor: 22.113

9.  Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells.

Authors:  Francesca M Rossi; Maria Ilaria Del Principe; Davide Rossi; Maria Irno Consalvo; Fabrizio Luciano; Antonella Zucchetto; Pietro Bulian; Riccardo Bomben; Michele Dal Bo; Marco Fangazio; Dania Benedetti; Massimo Degan; Gianluca Gaidano; Giovanni Del Poeta; Valter Gattei
Journal:  J Transl Med       Date:  2010-03-08       Impact factor: 5.531

10.  ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.

Authors:  Marta Crespo; Francesc Bosch; Neus Villamor; Beatriz Bellosillo; Dolors Colomer; María Rozman; Silvia Marcé; Armando López-Guillermo; Elies Campo; Emili Montserrat
Journal:  N Engl J Med       Date:  2003-05-01       Impact factor: 91.245

View more
  2 in total

1.  Combined normal donor and CLL: Single tube ZAP-70 analysis.

Authors:  Heba A Degheidy; David J Venzon; Mohammed Z H Farooqui; Fatima Abbasi; Diane C Arthur; Wyndham H Wilson; Adrian Wiestner; M A Stetler-Stevenson; Gerald E Marti
Journal:  Cytometry B Clin Cytom       Date:  2011-10-26       Impact factor: 3.058

2.  Quantitative detection of zeta-chain-associated protein 70 expression in chronic lymphocytic leukemia.

Authors:  Peixuan Zhu; Heba A Degheidy; Gerald E Marti; Shuhong Li; Fatima Abbasi; Adrian Wiestner; Platte Amstutz; Cha-Mei Tang
Journal:  Leuk Lymphoma       Date:  2012-08-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.